Daré Bioscience, Inc.
DARE$21M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSAN DIEGO21 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
DARE News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
DARE-BV1clindamycin phosphate vaginal gel, 2%
Bacterial Vaginosis
Tamoxifen
Vulvar Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DARE-BV1clindamycin phosphate vaginal gel, 2% | Phase 3 | Bacterial Vaginosis | - | - |
Tamoxifen | Phase 2 | Vulvar Atrophy | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply